stockrow
Friday 6 November 2026
Export PTPI’s income statement to Excel — free account
Petros Pharmaceuticals, Inc.
PTPI Healthcare Drug Manufacturers Specialty & Generic
Petros Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $5.1 million, down 12.2% from fiscal 2023.
- Revenue
- +299.1%
- EPS
- +75.0%
- Free cash flow
- +71.3%
Quarter to June 2026, against a year earlier
0.00
0.00
NaN
Follow PTPI
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (710.28%) | 894.47% | 1,575.70% | (1,396.12%) |
+8 more TTM periods Free account |
|
| (334.15%) | (317.66%) | (458.45%) | (337.43%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(2,608.36%) | (1,972.57%) | (1,261.45%) | (1,343.81%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.08) | (0.13) | (0.24) | (0.11) | |
Free Cash Flow |
(3.72) | (5.86) | (6.73) | (4.84) | |
| Other line items | |||||
Cash ROIC |
(88.69%) | (95.67%) | (84.10%) | (51.24%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Operating CF/Net income |
0.20 | 0.17 | 0.19 | 0.11 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.08) | (0.13) | (0.24) | (0.11) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 26 Oct 2026